期刊文献+

骨髓增殖性肿瘤与缺血性卒中

Myeloproliferative Neoplasms and Ischemic Stroke
下载PDF
导出
摘要 骨髓增殖性肿瘤常出现血管并发症,最常累及脑血管,以缺血性卒中最为常见。骨髓增殖性肿瘤作为缺血性卒中的病因之一,其诊断与治疗不同于其他病因所致卒中。白细胞增多、JAK2V617F基因突变等相继被发现与缺血性卒中相关。本文对骨髓增殖性肿瘤伴缺血性卒中的发生、机制及防治的新进展进行综述。 Myeloproliferative neoplasms (MPNs) often occur with vascular complications, most commonly involving cerebrovascular, and ischemic stroke is the most common. MPNs as a cause of ischemic stroke are different to other causes of stroke in diagnosis and treatment. And leukocytosis and JAK2V617F mutations have been found associated with ischemic stroke. In this paper, an updated overview of morbidity and pathogenesis, prevention and treatment in MPNs with ischemic stroke is presented.
作者 白贝贝 陈烨
出处 《中国卒中杂志》 2013年第7期585-589,共5页 Chinese Journal of Stroke
关键词 骨髓增殖性肿瘤 缺血性卒中 血栓形成 JAK2V617F突变 Myeloproliferative neoplasms Ischemic stroke Thrombosis JAK2V617Fmutation
  • 相关文献

参考文献30

  • 1Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes[J]. Blood, 2009, 114:937-951.
  • 2Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms[J]. Haematologica, 2011, 96:183-186.
  • 3Colombi M, Radaelli F, Zocchi L, et al. Thrombotic and hemorrhagic complications in essentialthrombocythemia. A retrospective study of 103 patients[J]. Cancer, 1991, 67:2926-2930.
  • 4Jensen MK, de Nully Brown P, Nielsen O J, et al Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area[J]. Eur J Haematol, 2000, 65:132-139.
  • 5Chim CS, Kwong YL, Lie AK, et al. Long- term outcome of 231 patients with essential thrombocythemia:prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia[J]. Arch Intern Med, 2005, 165:2651-2658.
  • 6Reisner SA, Rinkevich D, Markiewicz W, et al. Cardiac involvement in patients with myeloproliferative disorders[J]. Am J Med, 1992 93:498-504.
  • 7Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia:a study of the predictive factors in a series of 148 patients[J]. Leukemia, 1999, 13:150-154.
  • 8Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera:long-term results in 163 patients[J]. Haematologica, 2000, 85:1011-1018.
  • 9Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera[J]. J Clin Oncol, 2005, 23:2224- 2232.
  • 10Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm:assessment of value in a series of 664 consecutive patients[J]. Mayo Clin Proc, 2008 83:457-459.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部